Company Analysis
Sign in

Pyxis Oncology, Inc. (PYXS)

Nasdaq: PYXS · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2019
Full chart Alerts Compare
Grade4.6
◀ Past 5.6● Present 3.3▶ Future 5.1
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

14 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Pyxis Oncology, Inc.’s names, not what it holds today.

Patents granted
14
14 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
27
1 of them in 2025
Names they are printed under
4
a subsidiary, its own name
By yearGrantedApplications published
'12'13'14'15'16'17'18'19'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals1
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Apexigen, Inc. a subsidiary
US, as the owner printed on each patent
14 granted
8 published
Apexigen, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
17 published
Apexigen America, Inc. a subsidiary
US, as the owner printed on each patent
0 granted
1 published
Pyxis Oncology, Inc. its own name
US, as the owner printed on each patent
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Aug 3, 202111,078,283Anti-PD-L1 antibodies and methods of useBiotechnologyApexigen, Inc.
May 11, 202111,001,637Anti-CD40 antibodiesPharmaceuticalsApexigen, Inc.
Apr 16, 201910,259,878Anti-RANKL antibodies and methods of usePharmaceuticalsApexigen, Inc.
Jun 12, 20189,994,640Anti-CD40 antibodiesPharmaceuticalsApexigen, Inc.
Apr 24, 20189,951,136Anti-IL-6 receptor antibodies and methods of usePharmaceuticalsApexigen, Inc.
Jun 13, 20179,676,861Anti-CD40 antibodies and methods of usePharmaceuticalsApexigen, Inc.
Jan 31, 20179,556,278Anti-CD40 antibodiesPharmaceuticalsApexigen, Inc.
Sep 13, 20169,441,042Anti-KDR antibodies and methods of usePharmaceuticalsApexigen, Inc.
Feb 23, 20169,266,956Methods of inhibiting proliferation of CD40-expressing cancer cells with anti-CD40 antibodiesPharmaceuticalsApexigen, Inc.
Jul 21, 20159,085,621Anti-IL-1β antibodiesPharmaceuticalsApexigen, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0387499LIGAND-PAYLOAD CONJUGATESPharmaceuticalsPyxis Oncology, Inc.
Oct 10, 20242024/0336693BIOMARKERS FOR CD40 AGONIST THERAPYPharmaceuticalsApexigen, Inc.
Aug 1, 20242024/0252633METHODS OF TREATING CANCER WITH CD-40 AGONISTSPharmaceuticalsApexigen America, Inc.
May 16, 20242024/0158523ANTI-CD40 ANTIBODIES AND METHODS OF USEPharmaceuticalsApexigen, Inc.
Dec 21, 20232023/0406948ANTI-CD40 ANTIBODIES AND METHODS OF USEPharmaceuticalsApexigen, Inc.
Oct 26, 20232023/0340112ANTI-SIRPA ANTIBODIES AND METHODS OF USEBiotechnologyApexigen, Inc.
Nov 24, 20222022/0372154ANTI-TNFR2 ANTIBODIES AND METHODS OF USEPharmaceuticalsApexigen, Inc.
Feb 17, 20222022/0049006ANTI-CD40 ANTIBODIES AND METHODS OF USEPharmaceuticalsApexigen, Inc.
Feb 17, 20222022/0049005ANTI-CD40 ANTIBODIES AND METHODS OF USEPharmaceuticalsApexigen, Inc.
May 13, 20212021/0139594ANTI-CD40 ANTIBODIES IN COMBINATION AND METHODS OF USEPharmaceuticalsApexigen, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 4.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton PYXS · research, not advice